Brett Simpson
Brett is a co-founder of Arete (formed in 2000) and is based in the firm's London office. He focuses on the global semiconductor component sector. Brett is a regular public speaker at industry events and after 17 years looking at the sector, has a wealth of experience to draw on. Prior to Arete, Brett spent two years at Goldman Sachs in an equity analyst role, specialising in European technology following three years with Ericsson UK, working in business development, covering all aspects of wireline and wireless telecom infrastructure.
Mike Henry
Ian Buck
Ian Buck is vice president of NVIDIA's Accelerated Computing business unit, which includes all hardware and software product lines, third-party enablement, and marketing activities for GPU computing.
Buck joined NVIDIA in 2004 and created CUDA, which remains the established leading platform for accelerated-based parallel computing. Before joining NVIDIA, he was the development lead on Brook, which was the forerunner to generalized computing on GPUs.
Buck holds a Ph.D. in computer science from Stanford University and Bachelor of Science in computer science from Princeton University.
Joy Chen
Malcolm Faers
Chris Urch
I did my first degree at Cambridge reading natural sciences and chemistry. I stayed at Cambridge to complete my PhD on organic synthesis with Professor Ian Fleming and then moved to the United States to undertake post-doctoral research, again on organic synthesis, with Professor Barry Trost. On returning to this country I started work for ICI Agrochemicals where I remained for 16 years as it became Zeneca and eventually Syngenta. During this time, I worked on both fungicide and insecticide research, principally sterol biosynthesis inhibitors and acetylcholine receptor agonists respectively.
After leaving Syngenta I joined Amura, a start-up company in Cambridge. Amura was developing antibiotics and in particular a β-lactamase inhibitor. I stayed with Amura for three years and then joined Glycoform for six years, a spin-out from the University of Oxford, where I was the Research Director. Glycoform researched various ways of improving pharmaceuticals by the use of sugars.
After leaving Glycoform I worked as a consultant, increasingly for Redag Crop Protection who are researching novel agrochemicals. Four years ago, I joined them full time as Head of Chemistry.